SAN DIEGO — Coadministration of the long-acting amylin analog cagrilintide plus the glucagon-like peptide-1 (GLP-1) agonist semaglutide, dubbed CagriSema, resulted in significantly greater weight loss ...

SAN DIEGO -- Treatment with semaglutide 2.4 mg co-administered with the investigational long-acting amylin analogue cagrilintide (known together as CagriSema) led to improvements in glycemic control ...

An important international trial shows that combining cagrilintide and semaglutide helps adults with obesity achieve more dramatic weight loss and better metabolic health than current single-drug ...

TUCSON, AZ / ACCESS Newswire / February 2, 2026 / Umbrella Labs today announced an expanded research procurement program for cagrilintide peptide to support laboratories running amylin receptor ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

LONDON, Dec 20 (Reuters) - The CEO of Danish drugmaker Zealand Pharma (ZELA.CO), opens new tab said on Friday that data posted by Novo Nordisk's (NOVOb.CO), opens new tab late-stage study of its ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

An early study of a new experimental drug to treat obesity known as cagrilintide shows that, when combined with semaglutide 2.4 mg, the combination leads to more weight loss than semaglutide 2.4 mg ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

An early study of a new experimental drug to treat obesity known as cagrilintide shows that, when combined with semaglutide 2.4 mg, the combination leads to more weight loss than semaglutide 2.4 mg ...

Positive results show that the average weight loss was 12.5 kg (11.8% body weight reduction) with cagrilintide compared to 2.5 kg (2.3%) with placebo, after 68 weeks *1,2 Cagrilintide was ...